Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

BOTA 2.16 -0.03 (-1.37%)
price chart
Biota Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global ...
ATLANTA, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited ...
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
The gross profit margin for BIOTA PHARMACEUTICALS INC is currently lower than what is desirable, coming in at 34.92%. It has decreased significantly from the same period last year.
Related articles »  
Short Interest Update on Biota Pharmaceuticals, Inc. (NASDAQ:BOTA)
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) ensharesed a drop of 20.6% or -9,860 shares in the short positions. The number dropped from 47,978 on July 15,2015 to 38,118 on July 31,2015.
Biota Pharmaceuticals, Inc. (BOTA) Files Form 4 Insider Buying : Anne Vanlent ...
Biota Pharmaceuticals, Inc. (BOTA): Anne Vanlent , director of Biota Pharmaceuticals, Inc. purchased 35,000 shares on Jun 22, 2015.
Biota Pharmaceuticals Director Anne Vanlent Buys 35000 Shares (BOTA)  Dakota Financial News
What after Joseph Patti's Insider Purchase of Biota Pharmaceuticals Inc ...
Joseph Patti; that is an insider in Biota Pharmaceuticals Inc (NASDAQ:BOTA) 2.16 -0.03 -1.55% who is the latest to obtain shares in the firm for which he is the current CEO.
Biota Pharmaceuticals Completes Acquisition of Anaconda Pharma
ATLANTA, June 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) ("Biota" or the "Company") announced today that it has completed the acquisition of Anaconda Pharma, a privately-held biotechnology company based in Paris, France.
Shares of Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) Rally 3.39%
Shares of Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) rose by 3.39% in the past week and 7.64% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 4.7% and the outperformance increases to 7.59% for the last 4 weeks.
Monday Pre-Market Ratings: Biota Pharmaceuticals, Inc. (BOTA), Entergy Texas ...  WallStreet Scope
Biota Pharmaceuticals to Acquire Anaconda Pharma
ATLANTA, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) (the "Company") announced today that it has entered into a definitive agreement to acquire Anaconda Pharma, a privately-held biotechnology company based in Paris, ...
Biota to Acquire Anaconda Pharma for Up-to-$38M  Genetic Engineering & Biotechnology News
Biota Pharmaceuticals: A Cash-Rich Biotech With An Expanding Pipeline (BOTA)
Biota Pharmaceuticals (NASDAQ:BOTA) is a biopharmaceutical company focused on the discovery and development of products to prevent and treat potentially life-threatening viral respiratory infectious diseases.
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains ...
While the termination of the BARDA contract in April 2014 that provided up $231 million for the development of laninamivir octanoate had a substantial negative effect on Biota in 2014 as it took away a source of major funding, the company has made ...